Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Navidea Biopharmaceuticals Inc NAVB

Healthcare Biotechnology
Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. The Company’s business is focused on... see more

Recent & Breaking News (GREY:NAVB)

Navidea Biopharmaceuticals, Inc. to Host Earnings Call

Accesswire March 8, 2018

Navidea Biopharmaceuticals, Inc. to Host Earnings Call

Accesswire November 8, 2017

Investor Network: Navidea Biopharmaceuticals, Inc. to Host Earnings Call

Accesswire August 9, 2017

Navidea Biopharmaceuticals Reports Second Quarter 2017 Financial Results

Business Wire August 8, 2017

Today's Research Report Coverage on Biotech Stocks -- Rexahn Pharma, Protalix BioTherapeutics, Navidea Biopharma, and Biostage

PR Newswire July 19, 2017

Navidea Enters Exclusive License and Distribution Agreement For India with Sayre Therapeutics

Business Wire June 20, 2017

Daily Technical Summary Reports on Biotech Stocks -- Illumina, Navidea Biopharma, Grifols, and Intercept Pharma

PR Newswire June 16, 2017

Navidea’s Commercial Partner, Norgine B.V., Launches LYMPHOSEEK® in Europe

Business Wire June 12, 2017

Navidea Biopharmaceuticals to Present at the 7th Annual LD Micro Invitational Investor Conference

Business Wire June 1, 2017

Biotech Stocks on Investors' Radar -- BioMarin Pharma, Eyegate Pharma, Navidea Biopharma, and Cellectar Biosciences

PR Newswire May 9, 2017

Research Reports Coverage on Biotech Stocks -- Inotek Pharma, Infinity Pharma, Navidea Biopharma, and Cellectar Biosciences

PR Newswire March 16, 2017

Research Reports Coverage on Biotech Stocks -- PharmAthene, Corcept Therapeutics, Navidea Biopharma, and Inotek Pharma

PR Newswire January 25, 2017

Navidea to Present at Upcoming Investor Conference

Business Wire January 6, 2017

Research Reports Coverage on Biotech Stocks -- Celldex Therapeutics, Amicus Therapeutics, Navidea Biopharma, and Concordia

PR Newswire December 2, 2016

12 Biggest Mid-Day Gainers For Friday

Benzinga.com  November 25, 2016

Mid-Day Market Update: Crude Oil Down 3.5%; Navidea Shares Spike Higher

Benzinga.com  November 25, 2016

Mid-Morning Market Update: Markets Open Higher; Ctrip.Com To Acquire Skyscanner

Benzinga.com  November 25, 2016

Navidea Reports 2016 Third Quarter Financial Results

Business Wire November 3, 2016

Navidea Biopharmaceuticals to Announce Third Quarter 2016 Financial Results on November 3, 2016

Business Wire October 27, 2016

Navidea Appoints Michael M. Goldberg, M.D. President and Chief Executive Officer

Business Wire September 26, 2016